Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) a clinical-stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the first patient has been dosed in the first Imago-sponsored Phase 2b clinical trial of bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). “We are excited to start this study. There are many patients with essential thrombocythemia in need of alternatives to the current stan

Click to view original post